OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Mass-produce cell and gene therapies presents the biopharma industry with a unique set of challenges.
While researchers are succeeding with developing cell therapies and gene therapies, bringing technologies and processes to mass-produce the treatments, in an emerging and regulated environment, presents the biopharma industry with a unique set of challenges, says Eric Langer, managing partner, BioPlan Associates, in an interview with BioPharm International.
Related Content:
BioBusiness | Manufacturing | Regulatory/GMP Compliance | Quality/GMPs | Manufacturing, Cell Therapies | Intellectual Property & Patents | BioPharm Videos | Development